Regeneron Says Its COVID-19 Combo Treatment Could Be Ready for People This Fall
During Regeneron's (NASDAQ: REGN) earnings call on Tuesday, Chief Scientific Officer George Yancopoulos told analysts that the company planned to start human trials of REGN-COV2, the company's experimental COVID-19 treatment, in June. That means that if results from those studies are positive, the antibody cocktail could be available for use by the end of summer or fall.
Remdesivir, a recently approved COVID-19 treatment from Gilead Sciences (NASDAQ: GILD), and Regeneron's antibody cocktail both emerged from an Ebola study. While Gilead was ready to test its older antiviral candidate against COVID-19 right off the bat, Regeneron quickly developed new antibodies that specifically bind to the SARS-CoV-2 spike protein.
Image source: Getty Images.
Source Fool.com
